Pfizer Completes NextWave Purchase, Nymox Completes Patient Enrollment: Healthcare Business Recap

In a Wednesday press release, Pfizer (NYSE:PFE) said that it has finalized its purchase of the privately-held NextWave Pharmaceuticals, a specialty pharmaceutical firm that concentrates upon the development and commercialization of products for treating attention deficit hyperactivity disorder (ADHD). After the transaction closes, Pfizer will hold exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension. The drug should be available in January.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Genentech, a Roche Group (RHHBY.PK) member, announced in a Wednesday release that it is granting the drug development firm Curis (NASDAQ:CRIS) worldwide rights for the development and commercialization of GDC-0917, a small molecule designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins. The latter is working to develop next generation targeted small molecule drug candidates for cancer treatment.

On Wednesday, Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported through a press release the completion of patient enrollment in the firm’s pivotal domestic Phase 3 NX02-0017 Study of NX-1207 for BPH. This trial is now closed to further enrollment and top-line results from the large Phase 3 study are expected late next year.

Don’t Miss: Nail in the Coffin for the Housing Recovery Story?